Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis

Journal of Interferon and Cytokine Research

Volumn 32, Issue 1, 2012, Pages 34-45

  Cheng, Jing ^a,b   Liu, Jianzhong ^a   Shi, Zhenqi ^a   Jules, Joel ^a   Xu, Duorong ^b   Luo, Shaokai ^b   Wei, Shi ^a   Feng, Xu ^a  

^a University of Alabama at Birmingham   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE; BONE MARROW CELL; CONTROLLED STUDY; CYTOPLASM; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AMINO ACID MOTIFS; ANIMALS; BONE AND BONES; BONE RESORPTION; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INTERFERON-GAMMA; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND;

EID: 84862962635     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0019     Document Type: Article

References (51)

1. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH. 2008. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118:3775-3789.
2. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179. (Pubitemid 27507987)
3. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. 2002. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277:44347-44356. (Pubitemid 36157870)
4. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189:1025-1031. (Pubitemid 29169819)
5. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342. (Pubitemid 40852708)
6. Cao J, Venton L, Sakata T, Halloran BP. 2003. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18:270-277. (Pubitemid 36125919)
7. Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C, Susa M. 2002. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony- stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 277:21971-21982. (Pubitemid 34952352)
8. Cope AP, Schulze-Koops H, Aringer M. 2007. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 25: S4-S11. (Pubitemid 350176262)
9. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh, J. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424. (Pubitemid 29453612)
10. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. 2003. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230. (Pubitemid 36519939)
11. Fata JE, Kong YY, Li J., Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Khokha R, Penninger JM. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41-50.
12. Feng X. 2005. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene 350:1-13.
13. Feng X, Novack DV, Faccio R, Ory DS, Aya K, Boyer MI, McHugh KP, Ross FP, Teitelbaum SL. 2001. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest 107:1137-1144. (Pubitemid 32422910)
14. Fox SW, Chambers TJ. 2000. Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem Biophys Res Commun 276:868-872.
15. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R. 2007. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117:122-132. (Pubitemid 46048459)
16. Gowen M, Mundy GR. 1986. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol 136:2478-2482. (Pubitemid 16136826)
17. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, Klaere S, Komnenovic V, Mimata H, Yoshimatsu H, Takahashi N, von Haeseler A, Bader M, Kilic SS, Ueta Y, Pifl C, Narumiya S, Penninger JM. 2009. Central control of fever and female body temperature by RANKL/RANK. Nature 462:505-509.
18. Huang W, O'Keefe RJ, Schwarz EM. 2003. Exposure to receptoractivator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther 5:R49-R59.
19. Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, Yamamoto T. 2000. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254:14-24. (Pubitemid 30066727)
20. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277:41147-41156. (Pubitemid 35215706)
21. Ji JD, Park-Min KH, Shen Z, Fajardo RJ, Goldring SR, McHugh KP, Ivashkiv LB. 2009. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol 183:7223-7233.
22. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191:495-502.
23. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 162:2562-2568. (Pubitemid 29309274)
24. Kamolmatyakul S, Chen W, Li YP. 2001. Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res 80:351-355. (Pubitemid 32501337)
25. Kim D, Mebius RE, MacMicking JD, Jung S, Cupedo T, Castellanos Y, Rho J, Wong BR, Josien R, Kim N, Rennert PD, Choi Y. 2000. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 192:1467-1478.
26. Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee HJ, Jeong D, Kim N, Choi Y, Lee SY. 2009. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 119:813-825
27. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira dS, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
28. Lacey DL, Erdmann JM, Teitelbaum SL, Tan H-L, Ohara J, Shioi A. 1995. Interleukin-4, interferon gamma and prostaglandin E impact the osteoclast forming potential of murine bone marrow macrophages in vitro. Endocrinol 136:2367-2376.
29. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan, J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi, I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176. (Pubitemid 28180851)
30. Liu J, Wang S, Zhang P, Said-Al-Naief N, Michalek SM, Feng X. 2009. Molecular mechanism of bifunctional role of lipopolysaccharide (LPS) in osteoclastogenesis. J Biol Chem 284:12512-12523.
31. Liu W, Xu D, Yang H, Xu H, Shi Z, Cao X, Takeshita S, Liu J, Teale M, Feng X. 2004. Functional identification of three RANK cytoplasmic motifs mediating osteoclast differentiation and function. J Biol Chem 279:54759-54769. (Pubitemid 40053221)
32. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der HA, Itie A, Wakeham A, Khoo W, Sasaki T, Cao ZD, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015-1024. (Pubitemid 29200984)
33. Lorenzo J, Horowitz M, Choi Y. 2008. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29:403-440. (Pubitemid 351831507)
34. Madyastha PR, Yang S, Ries WL, Key LL, Jr. 2000. IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. J Interferon Cytokine Res 20:645-652. (Pubitemid 30481717)
35. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking b3 integrins are osteosclerotic due to dysfunctional osteoclasts. J Clin Invest 105:433-440. (Pubitemid 30127243)
36. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue, J. 1999. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353-362. (Pubitemid 29359450)
37. Rho J, Altmann CR, Socci ND, Merkov L, Kim N, So H, Lee O, Takami M, Brivanlou AH, Choi Y. 2002. Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell Biol 21:541-549
38. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferongamma: an overview of signals, mechanisms and functions. J Leukocyte Biol 75:163-189. (Pubitemid 38174573)
39. Takahashi N, Mundy GR, Roodman GD. 1986. Recombinant human interferon-gamma inhibits formation of human osteoclast- like cells. J Immunol 137:3544-3549. (Pubitemid 17193314)
40. Takayanagi H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292-304. (Pubitemid 46480961)
41. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell 3:889-901. (Pubitemid 35460788)
42. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600-605.
43. Takeshita S, Kaji K, Kudo A. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15:1477-1488. (Pubitemid 30484517)
44. Taubman MA, Kawai T. 2001. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med 12:125-135. (Pubitemid 32429279)
45. Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289:1504-1508.
46. Vignery A, Niven-Fairchild T, Shepard MH. 1990. Recombinant murine interferon-gamma inhibits the fusion of mouse alveolar macrophages in vitro but stimulates the formation of osteoclast- like cells on implanted syngeneic bone particles in mice in vivo. J Bone Miner Res 5:637-644. (Pubitemid 20237563)
47. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman, RM, Choi Y. 1997. TRANCE (tumor necrosis factor [TNF]-related activation- induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186:2075-2080. (Pubitemid 28013694)
48. Xu D, Shi Z, McDonald J, Pan G, Cao X, Yu X, Feng X. 2004. Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. Biochem J 383:219-225. (Pubitemid 39446682)
49. Xu D, Wang S, Liu W, Liu J, Feng X. 2006. A novel RANK cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. J Biol Chem 281:4678-4690. (Pubitemid 43847727)
50. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
51. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H. 2002. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418:443-447. (Pubitemid 34826847)